PMV Pharmaceuticals, Inc. (PMVP) Wednesday announced positive interim data from the Phase 2 portion of Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors.
Data from the study showed confirmed responses in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types including ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma. Overall response rate (ORR) was 33%. ORR of 43% was observed among patients in ovarian cancer cohort with a median duration of response of 7.6 months.
The company plans to submit a New Drug Application for rezatapopt in platinum resistant/refractory ovarian cancer in the first quarter of 2027.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.